RT @AHDB_Dairy: An outline agreement has been reached for the UK to join the Comprehensive and Progressive Agreement for Trans-Pacific Part…
RT @AHDB_Dairy: In May, GB milk production reached an estimated 1,141m litres, with daily deliveries averaging around 36.8m litres per day.…
Plenty of inspiring women out there in Scotland- get your entry in or nominate someone.... #womenindairy… https://t.co/BkFR9cmWur
RT @ruminanthw: TODAY we have launched a NEW #UKDairyWelfare23 for the next 5 years. The strategy is designed to help the industry show pro…
RT @dairyuk: How #recyclable are milk containers? More recyclable than you think! Watch this video for more info: https://t.co/a9JWOzDaXK #…
The company has been given the go-ahead by the Veterinary Medicines Directorate (VMD) to market its Finadyne Transdermal non-steroidal, anti-inflammatory pour-on as a treatment for reducing pyrexia linked to acute mastitis.
MSD was previously granted a licence allowing it to claim the product is efficient in reducing pyrexia – a fever or abnormal increase in body temperature – associated with bovine respiratory disease (BRD).
It can now also claim the product – the first of its kind to treat animals – is effective in treating pyrexia related to acute mastitis.
Dr Martin Behr, technical manager at MSD Animal Health, said the latest licence gave veterinary surgeons and farmers a new option in the treatment of mastitis.
He added that cattle farmers who opted for the pour-on over injections could reduce the time it took them to treat cattle by more than 60%.
It would also reduce the stress experienced by cattle when restrained, he said.
“The single pour-on application means less stress for the animal, and milk from lactating cows can go back in the tank in just 36 hours. In addition, use of a pour-on NSAID means reduced use of needles and better animal well-being.”
(Farmers Weekly 18th May, 2016)